PI3K-AKT-mTOR pathway inhibitors;Les inhibiteurs de la voie PI3 kinase-AKT-mTOR

Bulletin du Cancer

Volumn 93, Issue 1, 2006, Pages 19-26

  Cortot, Alexis ^a   Armand, Jean Pierre ^a   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Molecular targeted agent; mTOR inhibitor; Signal transduction

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTIBODY; AP 23573; EVEROLIMUS; GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR ANTIBODY; HEAT SHOCK PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P110; RAPAMYCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER CELL; CANCER THERAPY; DIARRHEA; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FATIGUE; GLIOBLASTOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY CANCER; LYMPHOMA; MELANOMA; NAUSEA AND VOMITING; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; THROMBOCYTOPENIA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 33144472313     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 2002; 7: 376-89.
2. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16: 525-37.
3. Altomare DA, Lyons GE, Mitsuuchi Y, Cheng JQ, Testa JR. Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin. Oncogene 1998; 16: 2407-11.
4. Mende I, Malstrom S, Tsichlis PN, Vogt PK, Aoki M. Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene 2001; 20: 4419-23.
5. Mhashilkar AM, Stewart AL, Sieger K, Yang HY, Khimani AH, Ito I, et al. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. Mol Ther 2003; 8: 207-19.
6. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996; 273: 239-42.
7. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999; 344: 427-31.
8. Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997; 277: 99-101.
9. Castedo M, Roumier T, Blanco J, Ferri KF, Barretina J, Tintignac LA, et al. Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J 2002; 21: 4070-80.
10. Xu G, Kwon G, Cruz WS, Marshall CA, McDaniel ML. Metabolic regulation by leucine of translation initiation through the mTOR-signaling pathway by pancreatic beta-cells. Diabetes 2001; 50: 353-60.
11. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21: 99-102.
12. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
13. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992; 89: 9267-71.
14. Fuse E, Kuwabara T, Sparreboom A, Sausville EA, Figg WD. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol 2005; 45: 394-403.
15. Rini BI, Weinberg V, Shaw V, Scott J, Bok R, Park JW, et al. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer 2004; 101: 90-5.
16. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2: 1093-103.
17. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001; 61: 4003-9.
18. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005; 23: 4152-61.
19. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369: 756-8.
20. Wiederrecht GJ, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res 1995; 1: 53-71.
21. Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K, et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res 2005; 65: 5325-36.
22. Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 1996; 56: 3895-7.
23. Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. p53/p21 (CIP1) cooperate in enforcing rapamycin-induced G (1) arrest and determine the cellular response to rapamycin. Cancer Res 2001; 61: 3373-81.
24. Gibbons JJ, Discafani C, Peterson R, Hernandez R, Skotnicki J, Frost J. The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenograft in vivo. Proc Am Soc Cancer Res 2000; 40: 301.
25. Hidalgo M, Rowinsky E, Erlichman C, Drengler R, Marshall B, Adjei A, et al. CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: a phase I study. Proc Am Soc Clin Onco 2000; 19: 187; (abstr.726).
26. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22: 2336-47.
27. Alexandre J, Raymond E, Armand JP. Rapamycin and CCI-779. Bull Cancer 1999; 86: 808-11.
28. O'Reilly T, Vaxelaire J, Muller M, Fiebig HH, Hattenberger M, Lane HA. In vivo activity of RAD 001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 2002: 43; (abstr. 359).
29. Lane H, Schnell C, Theuer A, et al. Antiangiogenetic activity of RAD 001, an orally active anticancer agent. Proc Am Assoc Cancer Res 2002: 43; (abstr. 922).
30. O'Donnell A, Faivre S, Judson I, Delbado C, Brock C, Lane H, et al. A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours. Proc Am Soc Clin Onco 2003; 22: 200; (abstr. 803).
31. Clackson T, Metcalf CA, Rozamus LW, Knowles HL, Wardwell SD, Roses JB, et al. Regression of tumor xenografts in mice after oral administration of AP23573, a novel mTOR inhibitor that induces tumor starvation. Proc Am Assoc Cancer Res 2002: 43; (abstr. LB95).
32. Mita M, Rowinsky E, Goldston M, Mita AC, Chu Q, Syedet S, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AP23573, an mTOR Inhibitor, administered IV daily × 5 every other week in patients with refractory or advanced malignancies. Proc Am Soc Clin Onco 2004; 46: 3076; (abstr.).
33. Desai AA, Janisch L, Berk LR, Knowles HL, Rivera VM, Bedrosian CL, et al. A phase I trial of a novel mTOR inhibitor AP23573 administered weekly in patients with refractory or advanced malignancies. A pharmacokinetic and pharmacodynamic analysis. Proc Am Soc Clin Onco 2004; 46: 3150; (abstr.).
34. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-18.
35. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23: 5314-22.
36. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005; 104: 1045-8.
37. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23: 5294-304.
38. Carpentier AF. New therapeutic approaches in glioblastomas. Bull Cancer 2005; 92: 355-9.
39. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347-56.
40. Hipp S, Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 2005; 90: 1433-4.
41. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-23.
42. Dutcher JP, Hudes G, Motzer R, Ko YJ, Smith JW, Zonno K, et al. Preliminary report of a phase 1 study of intravenous (IV) CCI-779 given in combination with interferon-α (IFN) to patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2003; 22: 213; (abstr. 854).
43. Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 2003; 14: 931-7.
44. Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grunwald V, Weiss G, et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003; 9: 2887-92.
45. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-9.
46. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002; 62: 5645-50.
47. Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. p53/p21 (CIP1) cooperate in enforcing rapamycin-induced G (1) arrest and determine the cellular response to rapamycin. Cancer Res 2001; 61: 3373-81.
48. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-7.
49. Luo Y, Marx SO, Kiyokawa H, Koff A, Massague J, Marks AR. Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol 1996; 16: 6744-51.
50. Aguirre D, Boya P, Bellet D, Faivre S, Troalen F, Benard J, et al. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 2004; 9: 797-805.
51. Xu G, Zhang W, Bertram P, Zheng XF, McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 2004; 24: 893-900.